Mortality Rate and Acute Kidney Injury Prevalence Reduction in COVID-19 Critical Patients Treated with Hemoperfusion

Autores
Barriga Moreno, Adriana P.; Lozano Sanchez, Marcela; Barón Alvarez, Rafael A.; Cordoba, Juan P.; Aroca Martinez, Gustavo; Dianda, Daniela Fernanda; Gonzalez Torres, Henry; Musso, Carlos Guido
Año de publicación
2023
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Introduction: Coronavirus disease 2019 (COVID-19) induces organic damage mainly through the patient's immune overreaction. Hemoperfusion (HPF) can remove inflammatory cytokines and can reduce the negative effects of cytokine storm in COVID-19. We compared the mortality rate, inflammatory response, and acute kidney injury (AKI) prevalence among patients suffering from respiratory insufficiency secondary to COVID-19 treated with and without HPF with HA330 cartridge.Methods: Mortality rate, serum creatinine, and ferritin values were compared between patients suffering from respiratory insufficiency secondary to COVID-19 who received conventional treatment and another group of patients who additionally received four sessions of HPF with HA330.Results: Of 116 patients suffering from acute respiratory insufficiency secondary to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), one group (n: 84) received support treatment and the other group (n: 32) additionally received HPF with HA330 cartridge. Both groups had no renal disease and similar age and comorbidities at admission, except for obesity and mechanical ventilation requirement, which were significantly higher in the HPF group. Mortality rate (61% vs. 31%, P: 0.008), serum creatinine (1.4 vs. 0.5 mg/dl, P < 0.001), and post-HPF serum ferritin (2868 vs. 1675, P < 0.001) were significantly lower in the HPF group.Conclusion: Mortality rate, serum ferritin, and AKI were significantly reduced in critical COVID-19 patients who received HPF with HA330 cartridge than in those who did not receive it. These results were obtained despite the HPF group risk factors, such as obesity and mechanical ventilation, worsening its prognosis.
Fil: Barriga Moreno, Adriana P.. Clínica de la Mujer; Colombia
Fil: Lozano Sanchez, Marcela. Clínica de la Mujer; Colombia
Fil: Barón Alvarez, Rafael A.. Clínica de la Mujer; Colombia
Fil: Cordoba, Juan P.. Clínica de la Costa; Colombia
Fil: Aroca Martinez, Gustavo. Clínica de la Costa; Colombia
Fil: Dianda, Daniela Fernanda. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Clínica de la Costa; Colombia
Fil: Gonzalez Torres, Henry. Universidad Simón Bolívar; Colombia
Fil: Musso, Carlos Guido. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Medicina Traslacional e Ingeniería Biomédica - Hospital Italiano. Instituto de Medicina Traslacional e Ingeniería Biomédica.- Instituto Universitario Hospital Italiano de Buenos Aires. Instituto de Medicina Traslacional e Ingeniería Biomédica; Argentina
Materia
Acute kidney injury
COVID-19
hemoperfusion
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/255093
Acceder
id CONICETDig_d820245a885a614e87e18d04708d7cb1
oai_identifier_str oai:ri.conicet.gov.ar:11336/255093
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Mortality Rate and Acute Kidney Injury Prevalence Reduction in COVID-19 Critical Patients Treated with HemoperfusionBarriga Moreno, Adriana P.Lozano Sanchez, MarcelaBarón Alvarez, Rafael A.Cordoba, Juan P.Aroca Martinez, GustavoDianda, Daniela FernandaGonzalez Torres, HenryMusso, Carlos GuidoAcute kidney injuryCOVID-19hemoperfusionhttps://purl.org/becyt/ford/3.2https://purl.org/becyt/ford/3Introduction: Coronavirus disease 2019 (COVID-19) induces organic damage mainly through the patient's immune overreaction. Hemoperfusion (HPF) can remove inflammatory cytokines and can reduce the negative effects of cytokine storm in COVID-19. We compared the mortality rate, inflammatory response, and acute kidney injury (AKI) prevalence among patients suffering from respiratory insufficiency secondary to COVID-19 treated with and without HPF with HA330 cartridge.Methods: Mortality rate, serum creatinine, and ferritin values were compared between patients suffering from respiratory insufficiency secondary to COVID-19 who received conventional treatment and another group of patients who additionally received four sessions of HPF with HA330.Results: Of 116 patients suffering from acute respiratory insufficiency secondary to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), one group (n: 84) received support treatment and the other group (n: 32) additionally received HPF with HA330 cartridge. Both groups had no renal disease and similar age and comorbidities at admission, except for obesity and mechanical ventilation requirement, which were significantly higher in the HPF group. Mortality rate (61% vs. 31%, P: 0.008), serum creatinine (1.4 vs. 0.5 mg/dl, P < 0.001), and post-HPF serum ferritin (2868 vs. 1675, P < 0.001) were significantly lower in the HPF group.Conclusion: Mortality rate, serum ferritin, and AKI were significantly reduced in critical COVID-19 patients who received HPF with HA330 cartridge than in those who did not receive it. These results were obtained despite the HPF group risk factors, such as obesity and mechanical ventilation, worsening its prognosis.Fil: Barriga Moreno, Adriana P.. Clínica de la Mujer; ColombiaFil: Lozano Sanchez, Marcela. Clínica de la Mujer; ColombiaFil: Barón Alvarez, Rafael A.. Clínica de la Mujer; ColombiaFil: Cordoba, Juan P.. Clínica de la Costa; ColombiaFil: Aroca Martinez, Gustavo. Clínica de la Costa; ColombiaFil: Dianda, Daniela Fernanda. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Clínica de la Costa; ColombiaFil: Gonzalez Torres, Henry. Universidad Simón Bolívar; ColombiaFil: Musso, Carlos Guido. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Medicina Traslacional e Ingeniería Biomédica - Hospital Italiano. Instituto de Medicina Traslacional e Ingeniería Biomédica.- Instituto Universitario Hospital Italiano de Buenos Aires. Instituto de Medicina Traslacional e Ingeniería Biomédica; ArgentinaIndian Society of Nephrology2023-08info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/255093Barriga Moreno, Adriana P.; Lozano Sanchez, Marcela; Barón Alvarez, Rafael A.; Cordoba, Juan P.; Aroca Martinez, Gustavo; et al.; Mortality Rate and Acute Kidney Injury Prevalence Reduction in COVID-19 Critical Patients Treated with Hemoperfusion; Indian Society of Nephrology; Indian Journal of Nephrology; 34; 1; 8-2023; 56-580971-40651998-3662CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://indianjnephrol.org/mortality-rate-and-acute-kidney-injury-prevalence-reduction-in-covid-19-critical-patients-treated-with-hemoperfusion/info:eu-repo/semantics/altIdentifier/doi/10.4103/ijn.ijn_175_22info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T10:07:34Zoai:ri.conicet.gov.ar:11336/255093instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 10:07:34.432CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Mortality Rate and Acute Kidney Injury Prevalence Reduction in COVID-19 Critical Patients Treated with Hemoperfusion
title Mortality Rate and Acute Kidney Injury Prevalence Reduction in COVID-19 Critical Patients Treated with Hemoperfusion
spellingShingle Mortality Rate and Acute Kidney Injury Prevalence Reduction in COVID-19 Critical Patients Treated with Hemoperfusion
Barriga Moreno, Adriana P.
Acute kidney injury
COVID-19
hemoperfusion
title_short Mortality Rate and Acute Kidney Injury Prevalence Reduction in COVID-19 Critical Patients Treated with Hemoperfusion
title_full Mortality Rate and Acute Kidney Injury Prevalence Reduction in COVID-19 Critical Patients Treated with Hemoperfusion
title_fullStr Mortality Rate and Acute Kidney Injury Prevalence Reduction in COVID-19 Critical Patients Treated with Hemoperfusion
title_full_unstemmed Mortality Rate and Acute Kidney Injury Prevalence Reduction in COVID-19 Critical Patients Treated with Hemoperfusion
title_sort Mortality Rate and Acute Kidney Injury Prevalence Reduction in COVID-19 Critical Patients Treated with Hemoperfusion
dc.creator.none.fl_str_mv Barriga Moreno, Adriana P.
Lozano Sanchez, Marcela
Barón Alvarez, Rafael A.
Cordoba, Juan P.
Aroca Martinez, Gustavo
Dianda, Daniela Fernanda
Gonzalez Torres, Henry
Musso, Carlos Guido
author Barriga Moreno, Adriana P.
author_facet Barriga Moreno, Adriana P.
Lozano Sanchez, Marcela
Barón Alvarez, Rafael A.
Cordoba, Juan P.
Aroca Martinez, Gustavo
Dianda, Daniela Fernanda
Gonzalez Torres, Henry
Musso, Carlos Guido
author_role author
author2 Lozano Sanchez, Marcela
Barón Alvarez, Rafael A.
Cordoba, Juan P.
Aroca Martinez, Gustavo
Dianda, Daniela Fernanda
Gonzalez Torres, Henry
Musso, Carlos Guido
author2_role author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Acute kidney injury
COVID-19
hemoperfusion
topic Acute kidney injury
COVID-19
hemoperfusion
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.2
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Introduction: Coronavirus disease 2019 (COVID-19) induces organic damage mainly through the patient's immune overreaction. Hemoperfusion (HPF) can remove inflammatory cytokines and can reduce the negative effects of cytokine storm in COVID-19. We compared the mortality rate, inflammatory response, and acute kidney injury (AKI) prevalence among patients suffering from respiratory insufficiency secondary to COVID-19 treated with and without HPF with HA330 cartridge.Methods: Mortality rate, serum creatinine, and ferritin values were compared between patients suffering from respiratory insufficiency secondary to COVID-19 who received conventional treatment and another group of patients who additionally received four sessions of HPF with HA330.Results: Of 116 patients suffering from acute respiratory insufficiency secondary to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), one group (n: 84) received support treatment and the other group (n: 32) additionally received HPF with HA330 cartridge. Both groups had no renal disease and similar age and comorbidities at admission, except for obesity and mechanical ventilation requirement, which were significantly higher in the HPF group. Mortality rate (61% vs. 31%, P: 0.008), serum creatinine (1.4 vs. 0.5 mg/dl, P < 0.001), and post-HPF serum ferritin (2868 vs. 1675, P < 0.001) were significantly lower in the HPF group.Conclusion: Mortality rate, serum ferritin, and AKI were significantly reduced in critical COVID-19 patients who received HPF with HA330 cartridge than in those who did not receive it. These results were obtained despite the HPF group risk factors, such as obesity and mechanical ventilation, worsening its prognosis.
Fil: Barriga Moreno, Adriana P.. Clínica de la Mujer; Colombia
Fil: Lozano Sanchez, Marcela. Clínica de la Mujer; Colombia
Fil: Barón Alvarez, Rafael A.. Clínica de la Mujer; Colombia
Fil: Cordoba, Juan P.. Clínica de la Costa; Colombia
Fil: Aroca Martinez, Gustavo. Clínica de la Costa; Colombia
Fil: Dianda, Daniela Fernanda. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Clínica de la Costa; Colombia
Fil: Gonzalez Torres, Henry. Universidad Simón Bolívar; Colombia
Fil: Musso, Carlos Guido. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Medicina Traslacional e Ingeniería Biomédica - Hospital Italiano. Instituto de Medicina Traslacional e Ingeniería Biomédica.- Instituto Universitario Hospital Italiano de Buenos Aires. Instituto de Medicina Traslacional e Ingeniería Biomédica; Argentina
description Introduction: Coronavirus disease 2019 (COVID-19) induces organic damage mainly through the patient's immune overreaction. Hemoperfusion (HPF) can remove inflammatory cytokines and can reduce the negative effects of cytokine storm in COVID-19. We compared the mortality rate, inflammatory response, and acute kidney injury (AKI) prevalence among patients suffering from respiratory insufficiency secondary to COVID-19 treated with and without HPF with HA330 cartridge.Methods: Mortality rate, serum creatinine, and ferritin values were compared between patients suffering from respiratory insufficiency secondary to COVID-19 who received conventional treatment and another group of patients who additionally received four sessions of HPF with HA330.Results: Of 116 patients suffering from acute respiratory insufficiency secondary to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), one group (n: 84) received support treatment and the other group (n: 32) additionally received HPF with HA330 cartridge. Both groups had no renal disease and similar age and comorbidities at admission, except for obesity and mechanical ventilation requirement, which were significantly higher in the HPF group. Mortality rate (61% vs. 31%, P: 0.008), serum creatinine (1.4 vs. 0.5 mg/dl, P < 0.001), and post-HPF serum ferritin (2868 vs. 1675, P < 0.001) were significantly lower in the HPF group.Conclusion: Mortality rate, serum ferritin, and AKI were significantly reduced in critical COVID-19 patients who received HPF with HA330 cartridge than in those who did not receive it. These results were obtained despite the HPF group risk factors, such as obesity and mechanical ventilation, worsening its prognosis.
publishDate 2023
dc.date.none.fl_str_mv 2023-08
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/255093
Barriga Moreno, Adriana P.; Lozano Sanchez, Marcela; Barón Alvarez, Rafael A.; Cordoba, Juan P.; Aroca Martinez, Gustavo; et al.; Mortality Rate and Acute Kidney Injury Prevalence Reduction in COVID-19 Critical Patients Treated with Hemoperfusion; Indian Society of Nephrology; Indian Journal of Nephrology; 34; 1; 8-2023; 56-58
0971-4065
1998-3662
CONICET Digital
CONICET
url http://hdl.handle.net/11336/255093
identifier_str_mv Barriga Moreno, Adriana P.; Lozano Sanchez, Marcela; Barón Alvarez, Rafael A.; Cordoba, Juan P.; Aroca Martinez, Gustavo; et al.; Mortality Rate and Acute Kidney Injury Prevalence Reduction in COVID-19 Critical Patients Treated with Hemoperfusion; Indian Society of Nephrology; Indian Journal of Nephrology; 34; 1; 8-2023; 56-58
0971-4065
1998-3662
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://indianjnephrol.org/mortality-rate-and-acute-kidney-injury-prevalence-reduction-in-covid-19-critical-patients-treated-with-hemoperfusion/
info:eu-repo/semantics/altIdentifier/doi/10.4103/ijn.ijn_175_22
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
dc.publisher.none.fl_str_mv Indian Society of Nephrology
publisher.none.fl_str_mv Indian Society of Nephrology
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1842270007255367680
score 13.13397

Publicaciones similares